Chargement en cours...
Disease‐Modifying Treatments for Progressive Supranuclear Palsy
In recent years, research has focused on the development of disease‐modifying treatments for PSP, targeting mainly at tau dysfunction. However, the glycogen synthase kinase 3 inhibitor, tideglusib, and the microtubuli stabilizer, davunetide, both failed to show efficacy in recent double‐blind, place...
Enregistré dans:
| Publié dans: | Mov Disord Clin Pract |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2015
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6183250/ https://ncbi.nlm.nih.gov/pubmed/30363906 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mdc3.12142 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|